Myeloid Engager Pipeline

  • Projects

  • Indication
  • Discovery &
    Lead Selection
  • IND-enabling
  • Phase I
  • Phase II
  • Phase III
  • Ownership

  • LTZ-301 (CD79b)

  • B-cell Lymphoma, Autoimmune Disease

  • Global

  • LTZ-232

  • Solid Tumor ,
    Malignant Ascites

  • Global

  • LTZ-233

  • Solid Tumor

  • Global

  • LTZ-121 (Targeting Treg)

  • Solid Tumor

  • Global

Note: Mutiple early-stage projects to be disclosed

Follow Us
  • Stay ln Touch

    General Inquiries

    info@ltztherapeutics.com

    Business Development

    vivian.tian@ltztherapeutics.com
  • Locations

    Redwood City, USA

    1100 Island Dr., Suite 103, Redwood City, CA, 94065

    Shenzhen, China

    Room 209, Scientific Research Building, Tsinghua Hi-Tech Park, Nanshan District, Shenzhen, 518057

@ 2024 LTZ Therapeutics Inc., All Rights Reserved.

Privacy Policy | Term of Use | Contact Us

为了更好的呈现效果，移动端请竖屏浏览